fda warning letters compounded semaglutide 2025 september Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Drug compounders sue FDA over

At Revital Trichology & Wellness, we believe the future of medicine lies in combining: Science-backed regenerative approaches Lifestyle optimization Nutritional support Movement and exercise Sleep and recovery Hormonal balance Advanced longevity strategies Peptides like GHK-Cu represent an exciting emerging area but responsible use, patient education, and medical supervision remain critical.

Our offerings include Wegovy, Oral Wegovy, Zepbound, and Foundayo, each designed for chronic weight management

In September 2019 , the FDA approved Rybelsus , the first oral GLP-1 receptor agonist, available in 3 mg (starter dose), 7 mg, and 14 mg daily tablets

Step Therapy Requirements: Many plans in 2026 require 'step therapy.' This means they won't approve an expensive GLP-1 until you've first tried and failed with older, cheaper alternatives (like Metformin)